Results 111 to 120 of about 41,657 (198)

A Case Report of Myocardial Infarction Complicated With Blood Pressure Fluctuations Caused by Pheochromocytoma

The Journal of Clinical Hypertension, Volume 28, Issue 8, August 2026.
ABSTRACT Pheochromocytoma typically presents with sustained or paroxysmal hypertension, but initial manifestation as acute non‐ST‐segment elevation myocardial infarction (NSTEMI) is rare. Peri‐procedural hemodynamic fluctuations are often dramatic, making diagnosis and management challenging.
HuiPing Li, Wei Yang, Yu Feng, You Zhang, Ganxin Yan, ChuanYu Gao   +5 more
wiley   +1 more source

The therapeutic potential of atorvastatin in treatment of <i>G. lamblia</i> infected mice; <i>in silico</i>, parasitological, and histopathological study. [PDF]

Front Vet Sci
Mohamed K, Khodary M, Hamed D, Alhazmi A, Gattan HS, Alruhaili MH, Fadel EF, Elshabrawy HA, El-Kady AM.   +8 more
europepmc   +1 more source

Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1367-1378, August 2026.
Among Korean adults with type 2 diabetes and no prior cardiovascular disease, thiazolidinedione use was associated with a lower risk of the primary composite outcome of stroke, myocardial infarction, hospitalization for heart failure, and all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitor use. ABSTRACT Background Thiazolidinediones (TZDs)
Yun Young Choi, Jimin Jeon, Minyoul Baik, Joonsang Yoo, Jinkwon Kim   +4 more
wiley   +1 more source

Cost-Utility Analysis of High-Intensity Statins; Atorvastatin 40 and 80 mg versus Rosuvastatin 20 mg from Egyptian Public Payer's Perspective: A Markov Model. [PDF]

Int J Prev Med
Ibrahim A, ElSherbiny D, Alhussaini MA, Masroja A, Anan I.   +4 more
europepmc   +1 more source

The changing epidemiology of human type 2 diabetes–associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities

Journal of Internal Medicine, Volume 300, Issue 2, Page 131-152, August 2026.
Abstract Type 2 diabetes (T2D) is a major global health concern strongly associated with atherosclerosis and subsequent macrovascular complications. These complications are the leading cause of death among T2D patients. Despite a decline in cardiovascular events over the last decade, individuals with T2D still have an approximately doubled risk ...
Dania Al‐Sharify, Jiangming Sun, Andreas Edsfeldt   +2 more
wiley   +1 more source

Atorvastatin Attenuates Human Cardiac Fibroblast Activation, with Associated Changes in GATA4/MEF2C and Selected Fibrosis-Related microRNAs. [PDF]

Int J Mol Sci
Chomaničová N, Adamičková A, Cervenak Z, Valášková S, Gažová A, Kyselovic J.   +5 more
europepmc   +1 more source

Drug-Drug Interaction of Chiglitazar with Empagliflozin, Atorvastatin, and Valsartan: An Open-Label, Single-Center, Self-Control, 3-Period Study. [PDF]

Drug Des Devel Ther
Sheng L, Li X, Yu J, Yang X, Li H, Xu H.
europepmc   +1 more source

Atorvastatin and almonertinib-induced myopathy in a polypharmacy context: a case report. [PDF]

Front Cardiovasc Med
Zhou J, Yu L, Xu H.
europepmc   +1 more source

The Effect of Liraglutide on the Hypolipidemic, Anti-Inflammatory, and Antioxidant Properties of Atorvastatin Mediated via the Nrf2/HO-1 Signaling Pathway: In Vivo and In Silico Validation. [PDF]

Pharmaceutics
Kamar SA, Magdy YM, Abuamara TMM, Sedky AA, Al-Hazani TMI, Alhelf M, Zayed ES, A Yousef T, Al-Dakhil A, Abou-Krisha MM, Almehmadi SJ, Khedr S.   +11 more
europepmc   +1 more source

[Retracted] Atorvastatin increases lipopolysaccharide-induced expression of tumour necrosis factor-α-induced protein 8-like 2 in RAW264.7 cells. [PDF]

Exp Ther Med
Liu MW, Su MX, Zhang W, Wang L, Qian CY.
europepmc   +1 more source